Olanzapine resolved treatment-resistant cannabinoid hyperemesis syndrome in four patients
Four patients with cannabinoid hyperemesis syndrome that did not respond to standard treatments all improved after receiving olanzapine, an atypical antipsychotic.
Quick Facts
What This Study Found
All four cases of treatment-refractory CHS remitted after olanzapine treatment. Olanzapine blocks multiple neurotransmitter receptors involved in nausea and vomiting. The authors suggest it may be particularly useful when CHS presents alongside psychotic symptoms or agitation.
Key Numbers
4 patients. All had treatment-refractory CHS. All remitted with olanzapine. Olanzapine targets dopamine, serotonin, histamine, and muscarinic receptors involved in emesis.
How They Did This
Case series of 4 patients with treatment-refractory cannabinoid hyperemesis syndrome treated with olanzapine at a single institution. Clinical outcomes documented before and after olanzapine initiation.
Why This Research Matters
CHS is increasingly recognized as cannabis use grows, and some cases do not respond to standard anti-emetics or hot showers. Having additional treatment options for refractory cases addresses a real clinical gap.
The Bigger Picture
Cannabis cessation remains the definitive treatment for CHS, but patients often cannot or will not stop immediately. Olanzapine could serve as a bridge treatment for acute refractory episodes, borrowing from its established role in chemotherapy-induced nausea.
What This Study Doesn't Tell Us
Only 4 cases with no control group. Cannot rule out spontaneous resolution. No standardized dosing protocol reported. Single institution.
Questions This Raises
- ?What is the optimal olanzapine dose for CHS?
- ?Would it work as first-line treatment?
- ?Does it address the underlying pathophysiology or just mask symptoms?
- ?How does it compare to haloperidol, which has also been tried for CHS?
Trust & Context
- Key Stat:
- 4 of 4 treatment-refractory CHS cases remitted with olanzapine
- Evidence Grade:
- Very small case series with no controls. Preliminary signal only.
- Study Age:
- 2021 case series.
- Original Title:
- Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.
- Published In:
- Journal of psychiatric practice, 27(4), 316-321 (2021)
- Authors:
- Hsu, Jennifer(2), Herrmann, Zachary(2), Kashyap, Saurabh(2), Claassen, Cynthia
- Database ID:
- RTHC-03210
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is cannabinoid hyperemesis syndrome?
CHS is a condition in chronic cannabis users characterized by severe cyclical nausea, vomiting, and abdominal pain. It typically resolves only with cannabis cessation, though hot showers provide temporary relief.
Why might olanzapine work for CHS?
Olanzapine blocks multiple neurotransmitter receptors (dopamine, serotonin, histamine, muscarinic) involved in nausea and vomiting pathways, similar to its mechanism in treating chemotherapy-induced nausea.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03210APA
Hsu, Jennifer; Herrmann, Zachary; Kashyap, Saurabh; Claassen, Cynthia. (2021). Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.. Journal of psychiatric practice, 27(4), 316-321. https://doi.org/10.1097/PRA.0000000000000564
MLA
Hsu, Jennifer, et al. "Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.." Journal of psychiatric practice, 2021. https://doi.org/10.1097/PRA.0000000000000564
RethinkTHC
RethinkTHC Research Database. "Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case..." RTHC-03210. Retrieved from https://rethinkthc.com/research/hsu-2021-treatment-of-cannabinoid-hyperemesis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.